Jasper Therapeutics Past Earnings Performance
Past criteria checks 0/6
Jasper Therapeutics's earnings have been declining at an average annual rate of -29.9%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-29.9%
Earnings growth rate
98.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -82.2% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully
Jan 23
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth
Jul 31We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate
Feb 02Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely
Oct 14Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02
Aug 12Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?
Jun 19Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning
Nov 28We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth
Nov 23Revenue & Expenses BreakdownBeta
How Jasper Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -64 | 17 | 52 |
| 30 Sep 23 | 0 | -61 | 18 | 47 |
| 30 Jun 23 | 0 | -55 | 17 | 41 |
| 31 Mar 23 | 0 | -50 | 16 | 36 |
| 31 Dec 22 | 0 | -38 | 17 | 35 |
| 30 Sep 22 | 0 | -34 | 16 | 34 |
| 30 Jun 22 | 0 | -25 | 15 | 32 |
| 31 Mar 22 | 0 | -23 | 14 | 29 |
| 31 Dec 21 | 0 | -31 | 11 | 25 |
| 30 Sep 21 | 0 | -32 | 9 | 21 |
| 30 Jun 21 | 0 | -39 | 8 | 19 |
| 31 Mar 21 | 0 | -40 | 6 | 18 |
| 31 Dec 20 | 0 | -32 | 5 | 16 |
Quality Earnings: JSPR is currently unprofitable.
Growing Profit Margin: JSPR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JSPR is unprofitable, and losses have increased over the past 5 years at a rate of 29.9% per year.
Accelerating Growth: Unable to compare JSPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JSPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: JSPR has a negative Return on Equity (-82.18%), as it is currently unprofitable.